BOS-342 is under clinical development by Boston Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BOS-342’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BOS-342 overview
PRS-342 is under development for the treatment of solid tumor including metastatic hepatocellular carcinoma, Merkel cell carcinoma and melanoma. The therapeutic candidate is a bi-specific fusion protein construct composed of a CD137-specific anticalin and GPC3 targeting antibody linked through an Fc molecule. It is based on Anticalin technology. It is administered by intravenous route.
Boston Pharmaceuticals overview
Boston Pharmaceuticals (Boston Pharma) is a clinical-stage biopharmaceutical company. It develops highly engineered targeted therapies for serious liver diseases. The company’s pipeline products include BOS-580 an investigational fusion protein based on human IgG and FGF21 treats metabolic dysfunction-associated steatohepatitis (MASH); BOS-342 is an investigational bispecific antibody directed against glypican-3 (GPC3) and 4-1BB (CD137) bispecific antibody that targets hepatocellular carcinoma (HC). Boston Pharma is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BOS-342’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
